Literature DB >> 19440740

Use of molecular modeling, docking, and 3D-QSAR studies for the determination of the binding mode of benzofuran-3-yl-(indol-3-yl)maleimides as GSK-3beta inhibitors.

Ki Hwan Kim1, Irina Gaisina, Franck Gallier, Denise Holzle, Sylvie Y Blond, Andrew Mesecar, Alan P Kozikowski.   

Abstract

Molecular modeling and docking studies along with three-dimensional quantitative structure relationships (3D-QSAR) studies have been used to determine the correct binding mode of glycogen synthase kinase 3beta (GSK-3beta) inhibitors. The approaches of comparative molecular field analysis (CoMFA) and comparative molecular similarity index analysis (CoMSIA) are used for the 3D-QSAR of 51 substituted benzofuran-3-yl-(indol-3-yl)maleimides as GSK-3beta inhibitors. Two binding modes of the inhibitors to the binding site of GSK-3beta are investigated. The binding mode 1 yielded better 3D-QSAR correlations using both CoMFA and CoMSIA methodologies. The three-component CoMFA model from the steric and electrostatic fields for the experimentally determined pIC(50) values has the following statistics: R(2)(cv) = 0.386 nd SE(cv) = 0.854 for the cross-validation, and R(2) = 0.811 and SE = 0.474 for the fitted correlation. F (3,47) = 67.034, and probability of R(2) = 0 (3,47) = 0.000. The binding mode suggested by the results of this study is consistent with the preliminary results of X-ray crystal structures of inhibitor-bound GSK-3beta. The 3D-QSAR models were used for the estimation of the inhibitory potency of two additional compounds.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19440740      PMCID: PMC2955516          DOI: 10.1007/s00894-009-0498-x

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  46 in total

1.  Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418.

Authors:  Ratan Bhat; Yafeng Xue; Stefan Berg; Sven Hellberg; Mats Ormö; Yvonne Nilsson; Ann-Cathrin Radesäter; Eva Jerning; Per-Olof Markgren; Thomas Borgegård; Martin Nylöf; Alfredo Giménez-Cassina; Félix Hernández; Jose J Lucas; Javier Díaz-Nido; Jesús Avila
Journal:  J Biol Chem       Date:  2003-08-19       Impact factor: 5.157

2.  Novel GSK-3 inhibitors with improved cellular activity.

Authors:  Andrew J Peat; Dulce Garrido; Joyce A Boucheron; Stephanie L Schweiker; Scott H Dickerson; Jayme R Wilson; Tony Y Wang; Stephen A Thomson
Journal:  Bioorg Med Chem Lett       Date:  2004-05-03       Impact factor: 2.823

3.  3-(7-Azaindolyl)-4-arylmaleimides as potent, selective inhibitors of glycogen synthase kinase-3.

Authors:  Han-Cheng Zhang; Hong Ye; Bruce R Conway; Claudia K Derian; Michael F Addo; Gee-Hong Kuo; Leonard R Hecker; Diane R Croll; Jian Li; Lori Westover; Jun Z Xu; Richard Look; Keith T Demarest; Patricia Andrade-Gordon; Bruce P Damiano; Bruce E Maryanoff
Journal:  Bioorg Med Chem Lett       Date:  2004-06-21       Impact factor: 2.823

4.  Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases.

Authors:  Panagiotis Polychronopoulos; Prokopios Magiatis; Alexios-Leandros Skaltsounis; Vassilios Myrianthopoulos; Emmanuel Mikros; Aldo Tarricone; Andrea Musacchio; S Mark Roe; Laurence Pearl; Maryse Leost; Paul Greengard; Laurent Meijer
Journal:  J Med Chem       Date:  2004-02-12       Impact factor: 7.446

5.  Structural insight into nucleotide recognition in tau-protein kinase I/glycogen synthase kinase 3 beta.

Authors:  Masaaki Aoki; Takehiro Yokota; Ikuko Sugiura; Chizuko Sasaki; Tsukasa Hasegawa; Chieko Okumura; Koichi Ishiguro; Toshiyuki Kohno; Shigetoshi Sugio; Takao Matsuzaki
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-02-25

Review 6.  Glycogen synthase kinase 3: a drug target for CNS therapies.

Authors:  Ratan V Bhat; Samantha L Budd Haeberlein; Jesús Avila
Journal:  J Neurochem       Date:  2004-06       Impact factor: 5.372

7.  GSK-3-selective inhibitors derived from Tyrian purple indirubins.

Authors:  Laurent Meijer; Alexios-Leandros Skaltsounis; Prokopios Magiatis; Panagiotis Polychronopoulos; Marie Knockaert; Maryse Leost; Xiaozhou P Ryan; Claudia Alin Vonica; Ali Brivanlou; Rana Dajani; Claudia Crovace; Cataldo Tarricone; Andrea Musacchio; S Mark Roe; Laurence Pearl; Paul Greengard
Journal:  Chem Biol       Date:  2003-12

8.  Evaluation and comparison of 3D-QSAR CoMSIA models for CDK1, CDK5, and GSK-3 inhibition by paullones.

Authors:  Conrad Kunick; Kathrin Lauenroth; Karen Wieking; Xu Xie; Christiane Schultz; Rick Gussio; Daniel Zaharevitz; Maryse Leost; Laurent Meijer; Alexander Weber; Flemming S Jørgensen; Thomas Lemcke
Journal:  J Med Chem       Date:  2004-01-01       Impact factor: 7.446

9.  Synthesis and discovery of macrocyclic polyoxygenated bis-7-azaindolylmaleimides as a novel series of potent and highly selective glycogen synthase kinase-3beta inhibitors.

Authors:  Gee-Hong Kuo; Catherine Prouty; Alan DeAngelis; Lan Shen; David J O'Neill; Chandra Shah; Peter J Connolly; William V Murray; Bruce R Conway; Peter Cheung; Lori Westover; Jun Z Xu; Richard A Look; Keith T Demarest; Stuart Emanuel; Steven A Middleton; Linda Jolliffe; Mary Pat Beavers; Xin Chen
Journal:  J Med Chem       Date:  2003-09-11       Impact factor: 7.446

10.  Pharmacophore modeling, quantitative structure-activity relationship analysis, and in silico screening reveal potent glycogen synthase kinase-3beta inhibitory activities for cimetidine, hydroxychloroquine, and gemifloxacin.

Authors:  Mutasem O Taha; Yasser Bustanji; Mohamed A S Al-Ghussein; Mohammad Mohammad; Hiba Zalloum; Ihab M Al-Masri; Naji Atallah
Journal:  J Med Chem       Date:  2008-03-07       Impact factor: 7.446

View more
  3 in total

1.  Structure-guided design of a highly selective glycogen synthase kinase-3β inhibitor: a superior neuroprotective pyrazolone showing antimania effects.

Authors:  Wenwen Chen; Irina N Gaisina; Hendra Gunosewoyo; Sam A Malekiani; Taleen Hanania; Alan P Kozikowski
Journal:  ChemMedChem       Date:  2011-07-12       Impact factor: 3.466

2.  Pharmacophore-based screening and drug repurposing exemplified on glycogen synthase kinase-3 inhibitors.

Authors:  Luminita Crisan; Sorin Avram; Liliana Pacureanu
Journal:  Mol Divers       Date:  2017-01-21       Impact factor: 2.943

3.  From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.

Authors:  Irina N Gaisina; Franck Gallier; Andrei V Ougolkov; Ki H Kim; Toru Kurome; Songpo Guo; Denise Holzle; Doris N Luchini; Sylvie Y Blond; Daniel D Billadeau; Alan P Kozikowski
Journal:  J Med Chem       Date:  2009-04-09       Impact factor: 7.446

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.